Cerebral Edema Treatment
04/15/20 • 74 min
Cerebral Edema Treatment
Special Guest: Aaron Cook, PharmD, BCCCP, BCPS, FCCP, FKSHP, FNCS
Show Notes: https://pharmacytodose.files.wordpress.com/2020/04/treatment-of-cerebral-edema-show-notes.pdf
Guideline Development
06:18 – How did the content and the chairs for this guideline get chosen?; 08:40 – How long were you working on these guidelines?; 09:40 – How are panel members chosen for the guidelines?; 11:20 – Is the research librarian underrated?; 13:31 – GRADE methodology and PICO formatting; 17:24 – Has this changed your research habits or ideas?; 21:40 – Challenges from meeting virtually when developing the guidelines; 23:53 – How were disagreements settled within the working group?
Management of Cerebral Edema
27:45 – Cerebral edema and elevated ICP; 29:22 – Refractory cerebral edema management; 31:59 – How long was the initial question list?; 35:03 – Quality of evidence; 37:58 – Patient subgroup with the most evidence; 40:10 – Should we be driving up patients’ sodium levels?; 44:56 – Is there a preferred hyperosmolar agent?; 47:45 – Mannitol in acute ischemic stroke; 49:00 – Osmolar therapy and neurologic outcomes; 51:16 – HTS administration; 54:30 – HTS ADE and monitoring; 57:10 – Mannitol osmolality monitoring; 58:20 – Hyperosmolar therapy ADE prevention; 61:00 – Guideline key take-aways; 62:20 – Common research issues
PharmacyToDose.Com
@PharmacyToDose on Twitter/Instagram
Learn more about your ad choices. Visit megaphone.fm/adchoices
Cerebral Edema Treatment
Special Guest: Aaron Cook, PharmD, BCCCP, BCPS, FCCP, FKSHP, FNCS
Show Notes: https://pharmacytodose.files.wordpress.com/2020/04/treatment-of-cerebral-edema-show-notes.pdf
Guideline Development
06:18 – How did the content and the chairs for this guideline get chosen?; 08:40 – How long were you working on these guidelines?; 09:40 – How are panel members chosen for the guidelines?; 11:20 – Is the research librarian underrated?; 13:31 – GRADE methodology and PICO formatting; 17:24 – Has this changed your research habits or ideas?; 21:40 – Challenges from meeting virtually when developing the guidelines; 23:53 – How were disagreements settled within the working group?
Management of Cerebral Edema
27:45 – Cerebral edema and elevated ICP; 29:22 – Refractory cerebral edema management; 31:59 – How long was the initial question list?; 35:03 – Quality of evidence; 37:58 – Patient subgroup with the most evidence; 40:10 – Should we be driving up patients’ sodium levels?; 44:56 – Is there a preferred hyperosmolar agent?; 47:45 – Mannitol in acute ischemic stroke; 49:00 – Osmolar therapy and neurologic outcomes; 51:16 – HTS administration; 54:30 – HTS ADE and monitoring; 57:10 – Mannitol osmolality monitoring; 58:20 – Hyperosmolar therapy ADE prevention; 61:00 – Guideline key take-aways; 62:20 – Common research issues
PharmacyToDose.Com
@PharmacyToDose on Twitter/Instagram
Learn more about your ad choices. Visit megaphone.fm/adchoices
Previous Episode
COVID-19
COVID-19
Special Guest: Andrew Barnes, PharmD
Dr. Andrew Barnes joins the podcast to discuss the effects of COVID-19. We talk about what Seattle and the University of Washington are doing to help treat this national pandemic. Plus there are plenty of tips throughout the episode for ways you can adapt to COVID-19 in your hospital or health system.
PharmacyToDose.Com
@PharmacyToDose on Twitter/Instagram
Learn more about your ad choices. Visit megaphone.fm/adchoices
Next Episode
Research Principles for COVID-19
Research Principles for COVID-19
Special Guest: Todd Miano, PharmD, PhD
Show Notes: https://pharmacytodose.files.wordpress.com/2020/04/research-principles-show-notes.pdf
05:19 – Todd’s interest in research/statistics; 09:18 – How Todd analyzes a research article; 24:22 – Why so much low-quality research for COVID-19?; 28:18 – In vitro v. in vivo; 32:34 – Risk of study errors in low-quality research; 45:43 – Publication bias; 51:50 – Interpreting outcome-based studies when patients are still critically ill; 54:46 – Ideal primary outcome for COVID-19 trials; 57:50 – Applying information from international data to US patients; 61:02 – What is the risk of using experimental drug treatments?; 68:54 – Effect of COVID-19 on non-COVID research; 70:33 – Advice for starting COVID-19 research; 73:43 – Research red flags; 75:46 – Keeping up with COVID-19 literature; 79:09 – Quarantine entertainment recommendations
PharmacyToDose.Com
@PharmacyToDose on Twitter/Instagram
Learn more about your ad choices. Visit megaphone.fm/adchoices
If you like this episode you’ll love
Episode Comments
Generate a badge
Get a badge for your website that links back to this episode
<a href="https://goodpods.com/podcasts/pharmacy-to-dose-the-critical-care-podcast-101887/cerebral-edema-treatment-5355205"> <img src="https://storage.googleapis.com/goodpods-images-bucket/badges/generic-badge-1.svg" alt="listen to cerebral edema treatment on goodpods" style="width: 225px" /> </a>
Copy